CriteriaEndocrinology and nutrition
Vascular protection in diabetes (Diabetes Canada 2018)
Shows which people with diabetes meet criteria for a statin, ACE inhibitor/ARB, aspirin and SGLT2i/GLP-1 RA to lower cardiovascular risk.
Updated 31 October 2026
When to use it
Review of cardioprotective therapy in adults with type 1 or type 2 diabetes.
Warning
Based on the 2018 chapter; later Diabetes Canada updates broaden SGLT2i and GLP-1 RA indications (heart failure, chronic kidney disease, high risk). Check the current version.
What it needs
- Diabetes type
- Age
- Clinical cardiovascular disease (coronary, cerebrovascular or peripheral arterial)
- Microvascular complications (retinopathy, nephropathy, neuropathy)
- Diabetes duration over 15 years
- Another cardiovascular risk factor or end-organ damage
- A1C above target on current therapy
- Estimated GFR > 30 mL/min/1.73 m²
The points for each answer and the automatic total are in the app.
How to interpret it
| Interpretation |
|---|
| Not indicated by these criteria; assess overall risk |
| Indicated (LDL target < 2.0 mmol/L or > 50 % reduction) |
In the app it also calculates: ACE inhibitor or ARB (vascular-protective dose), Aspirin 81–162 mg, SGLT2 inhibitor or GLP-1 RA with proven cardiovascular benefit.
Practical tip
Besides drugs, the guideline stresses overall control: healthy behaviours, blood pressure, glycaemia and smoking cessation.
3 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
